Drug Profile
CLP 1004
Alternative Names: CLP-1004Latest Information Update: 11 Mar 2016
Price :
$50
*
At a glance
- Originator Sorbent Therapeutics
- Class Polymers
- Mechanism of Action Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperkalaemia; Renal failure
Most Recent Events
- 11 Mar 2016 No recent reports on development identified - Phase-I for Hyperkalaemia in USA (unspecified route)
- 11 Mar 2016 No recent reports on development identified - Phase-I for Renal failure in USA (unspecified route)
- 24 Sep 2012 Phase-I clinical trials in Renal failure in USA (unspecified route)